Categories Earnings, Technology

KEMET reports better-than-expected Q1 2020 results

KEMET Corp. (NYSE: KEM) first quarter 2020 results beat Wall Street’s predictions and sent the stock up 7% in the pre-market trading hours. KEMET’s non-GAAP EPS of $0.82 was up 49% versus prior year first fiscal quarter, and exceeded the consensus outlook of $0.74. Sales of $345.2 million were up 5.4% year-over-year, and surpassed the analysts’ expectations of $343.58 million.

KEMET (KEM) Q1 2020 earnings - KEMET reports better-than-expected Q1 2020 resultsThe Fort Lauderdale, Florida-based firm’s GAAP net income was $40.3 million or $0.68 per share for the quarter ended June 30, 2019, compared to GAAP net income of $35.2 million or $0.60 per diluted share for the quarter ended June 30, 2018.

“While we are not immune to many of the factors affecting the passive component space, we are insulated to some degree by our Ceramics product line that focuses on high capacitance large case ceramics where the market remains tight, and by our growing Polymer product line,” said CEO William Lowe Jr.

Read: Abiomed (ABMD) misses Q1 2020 estimates; slashes FY20 outlook

Commenting on the outlook, he added, “As we look forward to the rest of our fiscal year, we expect adjusting inventory levels in the distribution channel, a slowdown in the automotive segment and Europe in general. However, going forward we expect to hold our gross margin in a similar range to this quarter from 33.5% to 35.0%, supported by our structural changes.”

In a separate announcement, the company said its Board of Directors declared a quarterly dividend of $0.05 per share. The dividend will be paid on August 26, 2019, to shareholders of record as of August 15, 2019.

Shares of KEMET have given a positive return of 15% since the beginning of this year and a negative return of 23% in the trailing 12 months.

We’re on Flipboard! Follow us to receive the latest stock market, earnings, and financial news at your fingertips

Most Popular

Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO

Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training

INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues

Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came

Riding the AI wave, Nvidia looks set to stay on the high-growth path

After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top